Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)

被引：0
|
作者：
Makoto Hosono
Hideharu Ikebuchi
Yoshihide Nakamura
Nobutaka Nakamura
Takahiro Yamada
Sachiko Yanagida
Asami Kitaoka
Kiyotaka Kojima
Hiroyasu Sugano
Seigo Kinuya
Tomio Inoue
Jun Hatazawa
机构：
[1] Kindai University,Faculty of Medicine
[2] Japanese Society of Nuclear Medicine,undefined
[3] Japan Radioisotope Association,undefined
[4] FUJIFILM RI Pharma Co.,undefined
[5] Ltd.,undefined
来源：
Annals of Nuclear Medicine | 2018年 / 32卷
关键词：
Lu-177-DOTA-TATE; Radionuclide therapy; Neuroendocrine tumor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.
引用
收藏
页码：217 / 235
页数：18
相关论文
共 16 条
  • [1] Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
    Hosono, Makoto
    Ikebuchi, Hideharu
    Nakamura, Yoshihide
    Nakamura, Nobutaka
    Yamada, Takahiro
    Yanagida, Sachiko
    Kitaoka, Asami
    Kojima, Kiyotaka
    Sugano, Hiroyasu
    Kinuya, Seigo
    Inoue, Tomio
    Hatazawa, Jun
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (03) : 217 - 235
  • [2] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
    Mc Ewan, A.
    Wieler, M.
    Makis, W.
    McMullen, T.
    Morrish, D.
    MacLeod, S.
    Schrader, L.
    Sawyer, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94
  • [3] 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
    Thakur, Shilpa
    Daley, Brianna
    Millo, Corina
    Cochran, Craig
    Jacobson, Orit
    Lu, Huiyan
    Wang, Zhantong
    Kiesewetter, Dale
    Chen, Xiaoyuan
    Vasko, Vasyl
    Klubo-Gwiezdzinska, Joanna
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1399 - 1409
  • [4] Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-Labeled DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [177Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles
    Kamaldeep
    Wanage, Gaurav
    Loharkar, Sarvesh
    Das, Tapas
    Basu, Sandip
    Banerjee, Sharmila
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (03) : 214 - 225
  • [5] Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Maarten O. van Aken
    Richard A. Feelders
    Wouter W. de Herder
    Boen L. R. Kam
    Martijn van Essen
    Eric P. Krenning
    Dik J. Kwekkeboom
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 749 - 755
  • [6] Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate
    de Keizer, Bart
    van Aken, Maarten O.
    Feelders, Richard A.
    de Herder, Wouter W.
    Kam, Boen L. R.
    van Essen, Martijn
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (04) : 749 - 755
  • [7] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy Lu-177-DOTA-TATE (PRRT) Improves Progression Free Survival (PFS) in Patients with Advanced Neuroendocrine Tumours (NETs)
    McEwan, A. J. B.
    Wieler, M.
    Sawyer, M. B.
    Morrish, D. W.
    Schaitel, B. A.
    Schrader, L. D.
    Murray, D.
    Makis, W.
    McMullen, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S158 - S158
  • [8] Incidence of raised HbA1c and correlation with Somatostatin analogue therapy (SSA) in patients with Neuroendocrine Tumours (NET) receiving peptide receptor [177Lu]Lu-DOTA-TATE radionuclide therapy (PRRT)
    Eftychiou, N.
    Ilyas, H.
    Ahmed, H.
    Hassan, F.
    Eccles, A.
    Lewington, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S469 - S470
  • [9] [DOTA, TYR3]octreotate, labeled with 177LU, is most promising for radionuclide therapy of somatostatin receptor-positive tumors.
    De Jong, M
    Breeman, WA
    Bernard, HF
    Bakker, WH
    Srinivasan, A
    Erion, J
    Bugaj, JE
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 111P - 111P
  • [10] Comparative analysis of cancer cell responses to peptide receptor radionuclide therapy with lutetium-177 labeled minigastrin analogue [177Lu]Lu-PP-F11N and external beam radiotherapy
    Grzmil, M.
    Boersema, P.
    Sharma, A.
    Blanc, A.
    Imobersteg, S.
    Pruschy, M.
    Picotti, P.
    Schibli, R.
    Behe, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S19 - S19
12